High Dose Insulin Therapy to Improve Liver Function
Primary Purpose
Hepatitis C Virus
Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Insulin
Sponsored by
About this trial
This is an interventional treatment trial for Hepatitis C Virus
Eligibility Criteria
Inclusion Criteria:
- Hepatitis C positive adult patients (serum HCV antibody positive)
- MELD score 6-15 at the time of inclusion
- Viral genotype "non-3"
- Not on antiviral therapy
Exclusion Criteria:
- HBV or HIV co-infection
- Evidence of hepatocellular carcinoma at the start of the trial either by imaging and or AFP levels above 400
- Undetectable HCV viral load (using HCV PCR test)
- Recent infection or bleeding (in the last 3 months)
Sites / Locations
- McGill University Helath Centre - (Royal Victoria Hospital)
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Insulin/dextrose clamp
Arm Description
Outcomes
Primary Outcome Measures
Liver status improvments (biochemical and histological)
Secondary Outcome Measures
Insulin resistance
Inflammatory mediators
Full Information
NCT ID
NCT01271140
First Posted
January 5, 2011
Last Updated
November 11, 2013
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
1. Study Identification
Unique Protocol Identification Number
NCT01271140
Brief Title
High Dose Insulin Therapy to Improve Liver Function
Official Title
High Dose Insulin Therapy to Improve Liver Function in Patients With HCV Liver Cirrhosis
Study Type
Interventional
2. Study Status
Record Verification Date
November 2013
Overall Recruitment Status
Unknown status
Study Start Date
January 2011 (undefined)
Primary Completion Date
December 2013 (Anticipated)
Study Completion Date
June 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Insulin resistance is one of the key factors in defining a progressive course of chronic Hepatitis C virus (HCV) infection and hepatic fibrosis. Multiple trials have targeted insulin resistance as an adjuvant way to manage hepatitis C liver disease with promising results.
Long term therapy using high dose insulin was shown to significantly reduce insulin resistance in obese patients. In cardiac and critically ill patients, long term insulin was shown to produce better outcomes mainly by reducing the overt inflammatory response. Furthermore, initial results of ongoing trials are revealing more benefits of insulin therapy. Using the (hyperinsulinimic normoglycemic clamp) for eight hours on patients undergoing major liver resection was able to maximize their liver function post-operatively. This trial also demonstrated inhibition of the inflammatory response, improvement in liver glycogen, inhibition of apoptosis and stimulation of liver regeneration.
Putting in mind the potential ability of the liver to regenerate and regain better function. The anti-inflammatory properties of insulin therapy along with its ability to reduce insulin resistance over time has led us to see the potential benefits of using insulin therapy on patients with chronic hepatitis C virus liver cirrhosis. Insulin will target the pathophysiology of the disease at a cellular and a molecular level.
The investigators theorize that long-term high insulin therapy would be able to promote better liver function and slow down fibrosis and injury in this population of patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis C Virus
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Insulin/dextrose clamp
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Insulin
Other Intervention Name(s)
Hyperinsulinemic normoglycemic clamp
Intervention Description
Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
Primary Outcome Measure Information:
Title
Liver status improvments (biochemical and histological)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Insulin resistance
Time Frame
6 months
Title
Inflammatory mediators
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hepatitis C positive adult patients (serum HCV antibody positive)
MELD score 6-15 at the time of inclusion
Viral genotype "non-3"
Not on antiviral therapy
Exclusion Criteria:
HBV or HIV co-infection
Evidence of hepatocellular carcinoma at the start of the trial either by imaging and or AFP levels above 400
Undetectable HCV viral load (using HCV PCR test)
Recent infection or bleeding (in the last 3 months)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Metrakos, MD
Organizational Affiliation
McGill University Health Centre/Research Institute of the McGill University Health Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
McGill University Helath Centre - (Royal Victoria Hospital)
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3A 1A1
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
High Dose Insulin Therapy to Improve Liver Function
We'll reach out to this number within 24 hrs